Sigrid Therapeutics Reports Significant Blood Sugar Reduction with Excellent Safety Profile in STAR Trial with…
Liu MingSeptember 26, 2019
First-in-Class MSP (mesoporous silica particle) based therapy targets blood sugar and other metabolic risk factors.…
MorganJuly 16, 2019
First-in-Class MSP (mesoporous silica particle) based therapy targets blood sugar and other metabolic risk factors…
MorganJune 4, 2019
Sigrid Therapeutics Announces SiPore15TM Selected for Oral Presentation at Upcoming 28th European Diabetics Congress in Edinburgh Novel silica…
MorganMay 21, 2019
Sigrid Therapeutics Announces SiPore15TM Data Presentation at the American Diabetes Association 79th Scientific Sessions …
MorganApril 9, 2019
Today you can read about Sigrid and our research in Svenska Dagbladet, one of Sweden’s…
MorganMarch 7, 2019
Nordic Life Science news recently published an article on our STAR Study! Read more about…
MorganMarch 4, 2019
Läs om vår banbrytande produkt och vår pågående forskningsstudie som söker deltagare. Tack till Mariefreds Tidning/Måsen för…
MorganFebruary 27, 2019
Sigrid Therapeutics has been featured on Uppgang, a local newspaper company. "Bioteknikföretaget Sigrid Therapeutics kan…
MorganFebruary 13, 2019